European Union approves blood thinner prasugrel

Published: 2009-03-06 06:59:00

Updated: 2009-03-06 06:59:00

The European Commission granted marketing authorization for the blood thinner prasugrel, which will be sold in Europe under the brand name Efient, according to Eli Lilly and Daiichi Sankyo who developed prasugrel.

The drug is designed to prevent dangerous blood clots from forming in patients w...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK